Cargando…
Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis
Despite the high prevalence of liver disease globally, there are currently no approved anti-fibrotic therapies to treat patients with liver fibrosis. A major goal in anti-fibrotic therapy is the development of drug delivery systems that allow direct targeting of the major pro-scarring cell populatio...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000Research
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955024/ https://www.ncbi.nlm.nih.gov/pubmed/27508067 http://dx.doi.org/10.12688/f1000research.8822.1 |